Atrial fibrillation in Brugada syndrome: Current perspectives.
Brugada syndrome
arrhythmia mechanism
atrial fibrillation
genetics
Journal
Journal of cardiovascular electrophysiology
ISSN: 1540-8167
Titre abrégé: J Cardiovasc Electrophysiol
Pays: United States
ID NLM: 9010756
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
06
11
2019
revised:
10
01
2020
accepted:
15
01
2020
pubmed:
22
1
2020
medline:
3
2
2021
entrez:
22
1
2020
Statut:
ppublish
Résumé
The incidence of atrial fibrillation (AF) in Brugada syndrome (BrS) has been reported at between 9% and 53% by different series, but the true prevalence is unknown. However, AF may be the presenting feature in some patients. The underlying mechanisms for AF may be a combination of multiple factors, genetic or acquired, that may impact upon autonomic function, atrial structure, and conduction velocities or other unknown factors. The presence of AF has been associated with a more malignant course, with a greater incidence of syncope and ventricular arrhythmias, thus acting as marker of more advanced disease. Regarding the management of patients with AF, antiarrhythmic drugs effective in preventing malignant arrhythmias in BrS such as quinidine or invasive treatment with pulmonary vein isolation (PVI) may be useful in AF treatment. In this review, we aim to present the current perspectives regarding the genetics, pathophysiology, management, and prognosis of AF in patients with BrS.
Substances chimiques
Anti-Arrhythmia Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
975-984Informations de copyright
© 2020 Wiley Periodicals, Inc.
Références
Sieira J, Brugada P. The definition of the Brugada syndrome. Eur Heart J. 2017;38:3029-3034.
Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. J Am Coll Cardiol. 1992;20:1391-1396.
Eckardt L, Kirchhof P, Loh P, et al. Brugada syndrome and supraventricular tachyarrhythmias: a novel association? J Cardiovasc Electrophysiol. 2001;12:680-685.
Itoh H, Shimizu M, Ino H, et al. Arrhythmias in patients with Brugada-type electrocardiographic findings. Jpn Circ J. 2001;65:483-486.
Morita H, Kusano-Fukushima K, Nagase S, et al. Atrial fibrillation and atrial vulnerability in patients with Brugada syndrome. J Am Coll Cardiol. 2002;40:1437-1444.
Bordachar P, Reuter S, Garrigue S, et al. Incidence, clinical implications and prognosis of atrial arrhythmias in Brugada syndrome. Eur Heart J. 2004;25:879-884.
Letsas KP, Sideris A, Efremidis M, et al. Prevalence of paroxysmal atrial fibrillation in Brugada syndrome: a case series and a review of the literature. J Cardiovasc Med. 2007;8:803-806.
Bigi MA, Aslani A, Shahrzad S. Clinical predictors of atrial fibrillation in Brugada syndrome. Europace. 2007;9:947-950.
Schimpf R, Giustetto C, Eckardt L, et al. Prevalence of supraventricular tachyarrhythmias in a cohort of 115 patients with Brugada syndrome. Ann Noninvasive Electrocardiol. 2008;13:266-269.
Giustetto C, Cerrato N, Gribaudo E, et al. Atrial fibrillation in a large population with Brugada electrocardiographic pattern: prevalence, management, and correlation with prognosis. Heart Rhythm. 2014;11:259-265.
Francis J, Antzelevitch C. Atrial fibrillation and Brugada syndrome. J Am Coll Cardiol. 2008;51:1149-1153.
Sacher F, Probst V, Maury P, et al. Outcome after implantation of a cardioverter-defibrillator in patients with Brugada syndrome: a multicenter study-part 2. Circulation. 2013;128:1739-1747.
Yan GX, Antzelevitch C. Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST-segment elevation. Circulation. 1999;100:1660-1666.
Wilde AA, Postema PG, Di Diego JM, et al. The pathophysiological mechanism underlying Brugada syndrome: depolarization versus repolarization. J Mol Cell Cardiol. 2010;49:543-553.
Yamashita T, Nakajima T, Hazama H, et al. Regional differences in transient outward current density and inhomogeneities of repolarization in rabbit right atrium. Circulation. 1995;92:3061-3069.
Conte G, Dewals W, Sieira J, et al. Drug-induced Brugada syndrome in children: clinical features, device-based management, and long-term follow-up. J Am Coll Cardiol. 2014;63:2272-2279.
Sacher F, Probst V, Iesaka Y, et al. Outcome after implantation of a cardioverter-defibrillator in patients with Brugada syndrome: a multicenter study. Circulation. 2006;114:2317-2324.
Pappone C, Radinovic A, Manguso F, et al. New-onset atrial fibrillation as first clinical manifestation of latent Brugada syndrome: prevalence and clinical significance. Eur Heart J. 2009;30:2985-2992.
Veltmann C, Kuschyk J, Schimpf R, et al. Prevention of inappropriate ICD shocks in patients with Brugada syndrome. Clin Res Cardiol. 2010;99:37-44.
Hernandez-Ojeda J, Arbelo E, Borras R, et al. Patients with Brugada syndrome and implanted cardioverter-defibrillators: long-term follow-up. J Am Coll Cardiol. 2017;70:1991-2002.
Priori SG, Wilde AA, Horie M, et al. Executive summary: HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. Europace. 2013;15:1389-1406.
Antzelevitch C, Brugada P, Borggrefe M, et al. Brugada syndrome: report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation. 2005;111:659-670.
Adler A. Brugada syndrome: diagnosis, risk stratification, and management. Curr Opin Cardiol. 2016;31:37-45.
Mascia G, Arbelo E, Hernandez-Ojeda J, Solimene F, Brugada R, Brugada J. Brugada syndrome and exercise practice: current knowledge, shortcomings and open questions. Int J Sports Med. 2017;38:573-581.
Martin CA, Matthews GD, Huang CL. Sudden cardiac death and inherited channelopathy: the basic electrophysiology of the myocyte and myocardium in ion channel disease. Heart. 2012;98:536-543.
Gussak I, Antzelevitch C, Bjerregaard P, Towbin JA, Chaitman BR. The Brugada syndrome: clinical, electrophysiologic and genetic aspects. J Am Coll Cardiol. 1999;33:5-15.
Antzelevitch C, Pollevick GD, Cordeiro JM, et al. Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death. Circulation. 2007;115:442-449.
Amin AS, Boink GJ, Atrafi F, et al. Facilitatory and inhibitory effects of SCN5A mutations on atrial fibrillation in Brugada syndrome. Europace. 2011;13:968-975.
Veerman CC, Wilde AA, Lodder EM. The cardiac sodium channel gene SCN5A and its gene product NaV1.5: role in physiology and pathophysiology. Gene. 2015;573:177-187.
Derangeon M, Montnach J, Baro I, Charpentier F. Mouse models of SCN5A-related cardiac arrhythmias. Front Physiol. 2012;3:210.
Pfeufer A, van Noord C, Marciante KD, et al. Genome-wide association study of PR interval. Nat Genet. 2010;42:153-159.
Pazoki R, de Jong JS, Marsman RF, et al. SNPs identified as modulators of ECG traits in the general population do not markedly affect ECG traits during acute myocardial infarction nor ventricular fibrillation risk in this condition. PLoS One. 2013;8:e57216.
Bezzina CR, Barc J, Mizusawa Y, et al. Common variants at SCN5A-SCN10A and HEY2 are associated with Brugada syndrome, a rare disease with high risk of sudden cardiac death. Nat Genet. 2013;45:1044-1049.
Sakata Y, Kamei CN, Nakagami H, Bronson R, Liao JK, Chin MT. Ventricular septal defect and cardiomyopathy in mice lacking the transcription factor CHF1/Hey2. Proc Natl Acad Sci USA. 2002;99:16197-16202.
Koibuchi N, Chin MT. CHF1/Hey2 plays a pivotal role in left ventricular maturation through suppression of ectopic atrial gene expression. Circ Res. 2007;100:850-855.
Fischer A, Klattig J, Kneitz B, et al. Hey basic helix-loop-helix transcription factors are repressors of GATA4 and GATA6 and restrict expression of the GATA target gene ANF in fetal hearts. Mol Cell Biol. 2005;25:8960-8970.
Gollob MH, Jones DL, Krahn AD, et al. Somatic mutations in the connexin 40 gene (GJA5) in atrial fibrillation. N Engl J Med. 2006;354:2677-2688.
Abraham RL, Yang T, Blair M, Roden DM, Darbar D. Augmented potassium current is a shared phenotype for two genetic defects associated with familial atrial fibrillation. J Mol Cell Cardiol. 2010;48:181-190.
Tan N, Chung MK, Smith JD, et al. Weighted gene coexpression network analysis of human left atrial tissue identifies gene modules associated with atrial fibrillation. Circ Cardiovasc Genet. 2013;6:362-371.
Christophersen IE, Holmegard HN, Jabbari J, et al. Rare variants in GJA5 are associated with early-onset lone atrial fibrillation. Can J Cardiol. 2013;29:111-116.
Hu D, Barajas-Martinez H, Burashnikov E, et al. A mutation in the beta 3 subunit of the cardiac sodium channel associated with Brugada ECG phenotype. Circ Cardiovasc Genet. 2009;2:270-278.
Olesen MS, Holst AG, Svendsen JH, Haunso S, Tfelt-Hansen J. SCN1Bb R214Q found in 3 patients: 1 with Brugada syndrome and 2 with lone atrial fibrillation. Heart Rhythm. 2012;9:770-773.
Ishikawa T, Takahashi N, Ohno S, et al. Novel SCN3B mutation associated with Brugada syndrome affects intracellular trafficking and function of Nav1.5. Circ J. 2013;77:959-967.
Kusano KF, Taniyama M, Nakamura K, et al. Atrial fibrillation in patients with Brugada syndrome relationships of gene mutation, electrophysiology, and clinical backgrounds. J Am Coll Cardiol. 2008;51:1169-1175.
Antzelevitch C. Brugada syndrome. Pacing Clin Electrophysiol. 2006;29:1130-1159.
Goldberger AL, Pavelec RS. Vagally-mediated atrial fibrillation in dogs: conversion with bretylium tosylate. Int J Cardiol. 1986;13:47-55.
Wang Z, Page P, Nattel S. Mechanism of flecainide's antiarrhythmic action in experimental atrial fibrillation. Circ Res. 1992;71:271-287.
Geddes LA, Hinds M, Babbs CF, et al. Maintenance of atrial fibrillation in anesthetized and unanesthetized sheep using cholinergic drive. Pacing Clin Electrophysiol. 1996;19:165-175.
Wang J, Liu L, Feng J, Nattel S. Regional and functional factors determining induction and maintenance of atrial fibrillation in dogs. Am J Physiol. 1996;271:H148-H158.
Nademanee K, Hocini M, Haissaguerre M. Epicardial substrate ablation for Brugada syndrome. Heart Rhythm. 2017;14:457-461.
Nademanee K, Raju H, de Noronha SV, et al. Fibrosis, connexin-43, and conduction abnormalities in the Brugada syndrome. J Am Coll Cardiol. 2015;66:1976-1986.
Letsas KP, Efremidis M, Vlachos K, et al. Right ventricular outflow tract high-density endocardial unipolar voltage mapping in patients with Brugada syndrome: evidence for electroanatomical abnormalities. Europace. 2018;20:f57-f63.
Toh N, Morita H, Nagase S, et al. Atrial electrophysiological and structural remodeling in high-risk patients with Brugada syndrome: assessment with electrophysiology and echocardiography. Heart Rhythm. 2010;7:218-224.
Nattel S, Burstein B, Dobrev D. Atrial remodeling and atrial fibrillation: mechanisms and implications. Circ Arrhythm Electrophysiol. 2008;1:62-73.
Tse G, Reddy S, Chopra J, et al. Electrocardiographic evidence of abnormal atrial phenotype in Brugada syndrome. J Electrocardiol. 2019;55:102-106.
Letsas KP, Weber R, Astheimer K, et al. Predictors of atrial tachyarrhythmias in subjects with type 1 ECG pattern of Brugada syndrome. Pacing Clin Electrophysiol. 2009;32:500-505.
Kofune M, Watanabe I, Ohkubo K, et al. Abnormal atrial repolarization and depolarization contribute to the inducibility of atrial fibrillation in Brugada syndrome. Int Heart J. 2010;51:159-165.
Nademanee K, Veerakul G, Mower M, et al. Defibrillator versus beta-blockers for unexplained death in Thailand (DEBUT): a randomized clinical trial. Circulation. 2003;107:2221-2226.
Priori SG, Blomstrom-Lundqvist C. 2015 European Society of Cardiology guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death summarized by co-chairs. Eur Heart J. 2015;36:2757-2759.
Antzelevitch C. The Brugada syndrome: ionic basis and arrhythmia mechanisms. J Cardiovasc Electrophysiol. 2001;12:268-272.
Shenthar J, Chakali SS, Acharya D, Parvez J, Banavalikar B. Oral quinine sulfate for the treatment of electrical storm and prevention of recurrent shocks in Brugada syndrome after failed cilostazol therapy. HeartRhythm Case Rep. 2017;3:470-474.
Gonzalez Corcia MC, de Asmundis C, Chierchia GB, Brugada P. Brugada syndrome in the paediatric population: a comprehensive approach to clinical manifestations, diagnosis, and management. Cardiol Young. 2016;26:1044-1055.
Nademanee K, Veerakul G, Chandanamattha P, et al. Prevention of ventricular fibrillation episodes in Brugada syndrome by catheter ablation over the anterior right ventricular outflow tract epicardium. Circulation. 2011;123:1270-1279.
Brugada J, Pappone C, Berruezo A, et al. Brugada syndrome phenotype elimination by epicardial substrate ablation. Circ Arrhythm Electrophysiol. 2015;8:1373-1381.
Pappone C, Brugada J, Vicedomini G, et al. Electrical substrate elimination in 135 consecutive patients with Brugada syndrome. Circ Arrhythm Electrophysiol. 2017;10:e005053.
de Asmundis C, Mugnai G, Chierchia GB, et al. Abnormally high risk of stroke in Brugada syndrome. J Cardiovasc Med. 2019;20:59-65.
Yang F, Hanon S, Lam P, Schweitzer P. Quinidine revisited. Am J Med. 2009;122:317-321.
Belhassen B, Rahkovich M, Michowitz Y, Glick A, Viskin S. Management of Brugada syndrome: thirty-three-year experience using electrophysiologically guided therapy with class 1A antiarrhythmic drugs. Circ Arrhythm Electrophysiol. 2015;8:1393-1402.
Michowitz Y, Milman A, Andorin A, et al. Characterization and management of arrhythmic events in young patients with Brugada syndrome. J Am Coll Cardiol. 2019;73:1756-1765.
Conte G, Chierchia GB, Wauters K, et al. Pulmonary vein isolation in patients with Brugada syndrome and atrial fibrillation: a 2-year follow-up. Europace. 2014;16:528-532.
Yamada T, Yoshida Y, Tsuboi N, et al. Efficacy of pulmonary vein isolation in paroxysmal atrial fibrillation patients with a Brugada electrocardiogram. Circ J. 2008;72:281-286.
Kitamura T, Fukamizu S, Kawamura I, et al. Long-term efficacy of catheter ablation for paroxysmal atrial fibrillation in patients with Brugada syndrome and an implantable cardioverter-defibrillator to prevent inappropriate shock therapy. Heart Rhythm. 2016;13:1455-1459.
Gonzalez Corcia MC, Sieira J, Pappaert G, et al. Implantable cardioverter-defibrillators in children and adolescents with Brugada syndrome. J Am Coll Cardiol. 2018;71:148-157.
Park DW, Nam GB, Rhee KS, Han GH, Choi KJ, Kim YH. Clinical characteristics of Brugada syndrome in a Korean population. Circ J. 2003;67:934-939.
Sarkozy A, Boussy T, Kourgiannides G, et al. Long-term follow-up of primary prophylactic implantable cardioverter-defibrillator therapy in Brugada syndrome. Eur Heart J. 2007;28:334-344.
Sacher F, Probst V, Bessouet M, et al. Remote implantable cardioverter defibrillator monitoring in a Brugada syndrome population. Europace. 2009;11:489-494.
Rodriguez-Manero M, Kreidieh B, Valderrabano M, et al. Ablation of atrial fibrillation in patients with Brugada syndrome: a systematic review of the literature. J Arrhythm. 2019;35:18-24.
Edvardsson N, Frykman V, van Mechelen R, et al. Use of an implantable loop recorder to increase the diagnostic yield in unexplained syncope: results from the PICTURE registry. Europace. 2011;13:262-269.
Krahn AD, Klein GJ, Yee R, Skanes AC. Randomized assessment of syncope trial: conventional diagnostic testing versus a prolonged monitoring strategy. Circulation. 2001;104:46-51.
Menozzi C, Brignole M, Garcia-Civera R, et al. Mechanism of syncope in patients with heart disease and negative electrophysiologic test. Circulation. 2002;105:2741-2745.
Moya A, Brignole M, Menozzi C, et al. Mechanism of syncope in patients with isolated syncope and in patients with tilt-positive syncope. Circulation. 2001;104:1261-1267.
Brignole M, Moya A, de Lange FJ, et al. 2018 ESC guidelines for the diagnosis and management of syncope. Eur Heart J. 2018;39:1883-1948.
Sacher F, Arsac F, Wilton SB, et al. Syncope in Brugada syndrome patients: prevalence, characteristics, and outcome. Heart Rhythm. 2012;9:1272-1279.
Kubala M, Aissou L, Traulle S, Gugenheim AL, Hermida JS. Use of implantable loop recorders in patients with Brugada syndrome and suspected risk of ventricular arrhythmia. Europace. 2012;14:898-902.
Rosso R, Glick A, Glikson M, et al. Outcome after implantation of cardioverter defibrillator [corrected] in patients with Brugada syndrome: a multicenter Israeli study (ISRABRU). Isr Med Assoc J. 2008;10:435-439.